β2-adrenergic Agonists Rescue Lysosome Acidification and Function in PSEN1 Deficiency by Reversing Defective ER-to-lysosome Delivery of ClC-7
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
SUMMARY Lysosomal dysfunction is considered pathogenic in Alzheimer Disease (AD). Loss of Presenilin-1 (PSEN1) function causing AD impedes acidification via defective vATPase V0a1 subunit delivery to lysosomes. We report that isoproterenol and related β2-adrenergic agonists re-acidify lysosomes in PSEN1 KO cells and fibroblasts from PSEN1 familial AD(FAD) patients, which restores lysosomal proteolysis, calcium homeostasis, and normal autophagy flux. We identify a novel rescue mechanism involving PKA-mediated facilitation of ClC-7 delivery to lysosomes which reverses markedly lowered Cl− content in PSEN1 KO lysosomes. Notably, PSEN1 loss-of-function impedes ER-to-lysosome delivery of ClC-7. Transcriptomics of PSEN1-deficient cells reveal strongly down-regulated ER-to-lysosome transport pathways and reversibility by isoproterenol thus accounting for lysosomal Cl− deficits that compound pH elevation due to deficient vATPase and rescue by β2-adrenergic agonists. Our findings uncover a broadened PSEN1 role in lysosomal ion homeostasis and novel pH modulation of lysosomes through β2-adrenergic regulation of ClC-7, which can potentially be modulated therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kimura, S., Noda, T., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4451 · Cited by 2,278 · cited 1×
“LC3 puncta fluorescing yellow correspond to autophagosomes (AP) or incompletely acidified/ unacidified autolysosomes (AL) and red appear in AL that were acidified upon fusion with lysosomes in vitro and in vivo [42, 43].”
BackgroundThe role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Self-citationLysosomal acidification mechanisms
Mindell, J. A. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142317 · Cited by 1,258
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 5×
“Procedures were performed as previously described [29].”
BackgroundMethodInfluentialSelf-citationAutophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities
Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.022 · Cited by 1,134 · cited 1×
“Lysosomal dysfunction is an early and critical factor in the pathogenesis of AD, and the promise of lysosomal remediation as an AD therapy is supported by studies in animal models of AD [5, 62, 63].”
ResultLoss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man
Kornak, U., Kasper, D., Bösl, M. R., Kaiser, E., Schweizer, M., Schulz, A., Friedrich, W., Delling, G., & Jentsch, T. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00206-9 · Cited by 995
Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
Yu, W. H., Cuervo, A. M., Kumar, A., Peterhoff, C. M., Schmidt, S. D., Lee, J.-H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505082 · Cited by 967 · cited 2×
“Live imaging was performed as previously described [72].”
MethodSelf-citationCompromised autophagy and neurodegenerative diseases
Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3961 · Cited by 851
Colacurcio, D. J., & Nixon, R. A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.05.004 · Cited by 548
Self-citationThe Cl-/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes
Graves, A. R., Curran, P. K., Smith, C. L., & Mindell, J. A. (2008) · Nature · doi:10.1038/nature06907 · Cited by 399 · cited 2×
“ClC-7 is a member of the H+/Cl− exchange transporter family and is the primary Cl− permeation pathway in the lysosome [13, 16].”
BackgroundLee, J.-H., McBrayer, M. K., Wolfe, D. M., Haslett, L. J., Kumar, A., Sato, Y., Lie, P. P. Y., Mohan, P., Coffey, E. E., Kompella, U., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.050 · Cited by 358 · cited 6×
“Isoproterenol β2-Adrenoreceptor agonist Sigma I2760 Salbutamol β2-Adrenoreceptor agonist Sigma S8260 FRSK activation of adenylyl cyclase, increase cAMP Sigma F3917 Rolipram PDE4 inhibitor, increase cAMP signaling Sigma R6520 Nicardipine L-type voltage-dependent Ca2+ channel blocker Sigma N7510 Resveratrol Antioxidant,…”
BackgroundResultInfluentialSelf-citationLysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A., & Krainc, D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.11.001 · Cited by 323
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
Liu, J., Lu, W., Reigada, D., Nguyen, J., Laties, A. M., & Mitchell, C. H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0675 · Cited by 141 · cited 2×
“antagonist (Nicardipine), Resveratrol [39], the a2A-AR agonist (Rilmenidine [40]) and the β2-AR agonist (Isoproterenol [41]), by assaying lysosomal pH restoration in PSEN1 KO cells (Figure 1A).”
BackgroundXue, X., Wang, L.-R., Sato, Y., Jiang, Y., Berg, M., Yang, D.-S., Nixon, R. A., & Liang, X.-J. (2014) · Nano Letters · doi:10.1021/nl501839q · Cited by 125 · cited 1×
“TFEB overexpression, cystatin B or C KO) and other modulations (acidic nanoparticles) [36, 38, 55, 56], which are challenging to translate into clinical therapies.”
BackgroundSelf-citation
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationMechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases
Nixon, R. A., & Rubinsztein, D. C. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00757-5 · Cited by 435
Self-citationThe aging lysosome: An essential catalyst for late-onset neurodegenerative diseases
Nixon, R. A. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140443 · Cited by 149
Self-citationIm, E., Jiang, Y., Stavrides, P. H., Darji, S., Erdjument-Bromage, H., Neubert, T. A., Choi, J. Y., Wegiel, J., Lee, J.-H., & Nixon, R. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1925 · Cited by 80
Self-citationMustaly-Kalimi, S., Gallegos, W., Marr, R. A., Gilman-Sachs, A., Peterson, D. A., Sekler, I., & Stutzmann, G. E. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211999119 · Cited by 55
“The critical role of ion gradients in lysosome function is also demonstrated in a recent study that implicates the chloride channel, CLC7, as a counter-ion conductance channel that regulates lysosomal pH, and loss of this channel exacerbates lysosomal dysfunction (60).”
Background
Metadata
- Authors
- Lee, J.-H., Wolfe, D. M., Darji, S., McBrayer, M. K., Colacurcio, D. J., Kumar, A., Stavrides, P., Mohan, P. S., & Nixon, R. A.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 432
- Issue
- 8
- Pages
- 2633-2650
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W3006732691
- Cited by
- 40
- References
- 16
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.